Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline Review, H1 2015

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline Review, H1 2015', provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview 8

Therapeutics Development 9

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Therapeutics under Development by Companies 11

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Therapeutics under Investigation by Universities/Institutes 18

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline Products Glance 21

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Products under Development by Companies 25

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Products under Investigation by Universities/Institutes 33

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Companies Involved in Therapeutics Development 35

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Therapeutics Assessment 115

Drug Profiles 134

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Recent Pipeline Updates 396

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Dormant Projects 593

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Discontinued Products 598

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Product Development Milestones 600

Appendix 610

List of Tables

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2015 24

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Comparative Analysis, H1 2015 25

Number of Products under Development by Companies, H1 2015 27

Number of Products under Development by Companies, H1 2015 (Contd..1) 28

Number of Products under Development by Companies, H1 2015 (Contd..2) 29

Number of Products under Development by Companies, H1 2015 (Contd..3) 30

Number of Products under Development by Companies, H1 2015 (Contd..4) 31

Number of Products under Development by Companies, H1 2015 (Contd..5) 32

Number of Products under Investigation by Universities/Institutes, H1 2015 34

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 35

Comparative Analysis by Late Stage Development, H1 2015 36

Comparative Analysis by Clinical Stage Development, H1 2015 37

Comparative Analysis by Early Stage Development, H1 2015 38

Comparative Analysis by Unknown Stage Development, H1 2015 39

Products under Development by Companies, H1 2015 40

Products under Development by Companies, H1 2015 (Contd..1) 41

Products under Development by Companies, H1 2015 (Contd..2) 42

Products under Development by Companies, H1 2015 (Contd..3) 43

Products under Development by Companies, H1 2015 (Contd..4) 44

Products under Development by Companies, H1 2015 (Contd..5) 45

Products under Development by Companies, H1 2015 (Contd..6) 46

Products under Development by Companies, H1 2015 (Contd..7) 47

Products under Investigation by Universities/Institutes, H1 2015 48

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 49

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by 4SC AG, H1 2015 50

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by AbbVie Inc., H1 2015 51

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 52

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Affimed Therapeutics AG, H1 2015 53

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Altor BioScience Corporation, H1 2015 54

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Amgen Inc., H1 2015 55

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 56

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Array BioPharma Inc., H1 2015 57

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 58

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by AstraZeneca Plc, H1 2015 59

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Bexion Pharmaceuticals, LLC., H1 2015 60

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Bio-Path Holdings, Inc., H1 2015 61

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Bristol-Myers Squibb Company, H1 2015 62

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Calithera Biosciences, Inc., H1 2015 63

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Cantargia AB, H1 2015 64

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Celator Pharmaceuticals, Inc., H1 2015 65

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Cellectis S.A., H1 2015 66

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 67

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Ceronco Biosciences, H1 2015 68

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Conkwest, Inc., H1 2015 69

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Constellation Pharmaceuticals, Inc., H1 2015 70

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 71

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 72

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by DiNonA Inc., H1 2015 73

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 74

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by EpiZyme, Inc., H1 2015 75

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Erytech Pharma SA, H1 2015 76

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Eureka Therapeutics, Inc., H1 2015 77

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Fate Therapeutics, Inc., H1 2015 78

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Formula Pharmaceuticals, Inc., H1 2015 79

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Gamida Cell Ltd., H1 2015 80

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by GlaxoSmithKline Plc, H1 2015 81

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Hangzhou Minsheng Pharmaceutical Group Co.,Ltd, H1 2015 82

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by iDD biotech SAS, H1 2015 83

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Immunomedics, Inc., H1 2015 84

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Incyte Corporation, H1 2015 85

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Interprotein Corporation, H1 2015 86

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Jasco Pharmaceuticals, LLC., H1 2015 87

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Johnson & Johnson, H1 2015 88

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Juno Therapeutics Inc., H1 2015 89

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 90

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 91

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Kiadis Pharma B.V., H1 2015 92

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Kite Pharma, Inc., H1 2015 93

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by medac GmbH, H1 2015 94

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by MedImmune, LLC, H1 2015 95

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Merck & Co., Inc., H1 2015 96

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 97

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Mirna Therapeutics, Inc., H1 2015 98

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Novartis AG, H1 2015 99

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by NuCana BioMed Limited, H1 2015 100

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Omeros Corporation, H1 2015 101

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Onconova Therapeutics, Inc., H1 2015 102

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 103

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by OriBase Pharma, H1 2015 104

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 105

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Pfenex Inc., H1 2015 106

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Pfizer Inc., H1 2015 107

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Pharma Mar, S.A., H1 2015 108

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Pharmacyclics, Inc., H1 2015 109

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Polyphor Ltd., H1 2015 110

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 111

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Priaxon AG, H1 2015 112

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Quimatryx, S.L., H1 2015 113

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Sanofi, H1 2015 114

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Sareum Holdings Plc, H1 2015 115

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Seattle Genetics, Inc., H1 2015 116

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Sellas Inc., H1 2015 117

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2015 118

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Sigma-Tau S.p.A., H1 2015 119

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 120

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 121

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Synta Pharmaceuticals Corp., H1 2015 122

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by TetraLogic Pharmaceuticals, H1 2015 123

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Theravectys S.A., H1 2015 124

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 125

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 126

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Tragara Pharmaceuticals, Inc., H1 2015 127

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Verastem, Inc., H1 2015 128

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Pipeline by Xenetic Biosciences plc, H1 2015 129

Assessment by Monotherapy Products, H1 2015 130

Assessment by Combination Products, H1 2015 131

Number of Products by Stage and Target, H1 2015 132

Number of Products by Stage and Mechanism of Action, H1 2015 140

Number of Products by Stage and Route of Administration, H1 2015 146

Number of Products by Stage and Molecule Type, H1 2015 148

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics-Recent Pipeline Updates, H1 2015 411

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Dormant Projects, H1 2015 608

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Dormant Projects (Contd..1), H1 2015 609

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Dormant Projects (Contd..2), H1 2015 610

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Dormant Projects (Contd..3), H1 2015 611

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Dormant Projects (Contd..4), H1 2015 612

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Discontinued Products, H1 2015 613

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Discontinued Products (Contd..1), H1 2015 614

List of Figures

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2015 24

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Comparative Analysis, H1 2015 25

Number of Products under Development by Companies, H1 2015 26

Number of Products under Investigation by Universities/Institutes, H1 2015 33

Comparative Analysis by Late Stage Development, H1 2015 36

Comparative Analysis by Clinical Stage Development, H1 2015 37

Comparative Analysis by Early Stage Products, H1 2015 38

Assessment by Monotherapy Products, H1 2015 130

Number of Products by Top 10 Targets, H1 2015 132

Number of Products by Stage and Top 10 Targets, H1 2015 132

Number of Products by Top 10 Mechanism of Actions, H1 2015 139

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 139

Number of Products by Top 10 Routes of Administration, H1 2015 145

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 145

Number of Products by Top 10 Molecule Types, H1 2015 147

Number of Products by Stage and Top 10 Molecule Types, H1 2015 147

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AbbVie Inc.

Actinium Pharmaceuticals, Inc.

Affimed Therapeutics AG

Altor BioScience Corporation

Amgen Inc.

Ariad Pharmaceuticals, Inc.

Array BioPharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

Bexion Pharmaceuticals, LLC.

Bio-Path Holdings, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Cantargia AB

Celator Pharmaceuticals, Inc.

Cellectis S.A.

Cellular Biomedicine Group, Inc.

Ceronco Biosciences

Conkwest, Inc.

Constellation Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc.

Daiichi Sankyo Company, Limited

DiNonA Inc.

Epirus Biopharmaceuticals, Inc.

EpiZyme, Inc.

Erytech Pharma SA

Eureka Therapeutics, Inc.

Fate Therapeutics, Inc.

Formula Pharmaceuticals, Inc.

Gamida Cell Ltd.

GlaxoSmithKline Plc

Hangzhou Minsheng Pharmaceutical Group Co.,Ltd

iDD biotech SAS

Immunomedics, Inc.

Incyte Corporation

Interprotein Corporation

Jasco Pharmaceuticals, LLC.

Johnson & Johnson

Juno Therapeutics Inc.

KaloBios Pharmaceuticals, Inc.

Karyopharm Therapeutics, Inc.

Kiadis Pharma B.V.

Kite Pharma, Inc.

medac GmbH

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Mirna Therapeutics, Inc.

Novartis AG

NuCana BioMed Limited

Omeros Corporation

Onconova Therapeutics, Inc.

Onyx Pharmaceuticals, Inc.

OriBase Pharma

Otsuka Holdings Co., Ltd.

Pfenex Inc.

Pfizer Inc.

Pharma Mar, S.A.

Pharmacyclics, Inc.

Polyphor Ltd.

Portola Pharmaceuticals, Inc.

Priaxon AG

Quimatryx, S.L.

Sanofi

Sareum Holdings Plc

Seattle Genetics, Inc.

Sellas Inc.

Sigma-Tau Pharmaceuticals, Inc

Sigma-Tau S.p.A.

Spectrum Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

TetraLogic Pharmaceuticals

Theravectys S.A.

Threshold Pharmaceuticals, Inc.

Tolero Pharmaceuticals, Inc.

Tragara Pharmaceuticals, Inc.

Verastem, Inc.

Xenetic Biosciences plc

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutic Products under Development, Key Players in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Overview, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com